THE SINGLE-DOSE TREATMENT OF CYSTITIS WIT H FOSFOMYCIN TROMETAMOL (MONURIL(R)) - AN ANALYSIS OF 15 CONTROLLED TRIALS ON 2048 PATIENTS

The results of analysis taking into account 15 controlled trials perfo rmed in women suffering from acute cystitis are presented. In each tri al, single-dose treatment with fosfomycin trometamol was tested and co mpared to either another single-dose treatment (6 trials), or a 3 - 7 day treatment (9 trials). The total number of patients enrolled in the trials is 2048. Short term bacteriological eradication was evaluated in 1540 patients with confirmed urinary tract infection and obtained i n 85.6 % of cases with fosfomycin trometamol, and in 86.7 % of cases w ith the other treatments. In patients who had completed long term foll ow-up, the eradication rate was 84.6 % with fosfomycin trometamol, and 79.6 % with the other treatments (statiscally significant difference, p < 0.05). A similar difference was observed during the long term che ck-up when fosfomycin trometamol was exclusively compared to the 3-7 d ay treatments (82.9 % and 77.5 % respectively), The comparison between different single-dose treatments showed identical efficacy at short t erm (84.7 %) and at long term (85.2 %) with fosfomycin trometamol comp ared to other single-dose treatments (84.8 % at short term, 85.5 % at long term). This analysis indicates that a single-dose treatment of ac ute cystitis with fosfomycin trometamol is at least as efficient as a 3-7 day treatment if not better, in the long term. Concerning safety, the single-dose and the 3-7 day regimens were found to be equivalent w ith regard to the number of side effects noted.